Last reviewed · How we verify
Brivaracetam (ucb 34714)
Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.
Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures. Used for Adjunctive treatment of partial-onset seizures in epilepsy, Generalized tonic-clonic seizures (pipeline indication).
At a glance
| Generic name | Brivaracetam (ucb 34714) |
|---|---|
| Sponsor | UCB Pharma |
| Drug class | Antiepileptic agent; SV2A ligand |
| Target | SV2A (synaptic vesicle protein 2A) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Brivaracetam is a high-affinity ligand for SV2A, a synaptic vesicle glycoprotein involved in neurotransmitter release and neuronal excitability. By binding to SV2A with greater selectivity and potency than levetiracetam, it modulates calcium-dependent exocytosis and reduces the release of excitatory neurotransmitters, thereby suppressing seizure activity. This mechanism makes it effective as an antiepileptic agent with a potentially improved tolerability profile.
Approved indications
- Adjunctive treatment of partial-onset seizures in epilepsy
- Generalized tonic-clonic seizures (pipeline indication)
Common side effects
- Somnolence
- Fatigue
- Dizziness
- Headache
- Irritability/mood changes
- Nausea
Key clinical trials
- Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (PHASE3)
- A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
- Epileptic Hippocampus in Alzheimer's Disease (PHASE1, PHASE2)
- A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (PHASE3)
- Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy (PHASE3)
- Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brivaracetam (ucb 34714) CI brief — competitive landscape report
- Brivaracetam (ucb 34714) updates RSS · CI watch RSS
- UCB Pharma portfolio CI